GlassScriptPhysician profile
William R Doheny
NPI 1194741991
$12,475.45
in general payments reported to CMS, 2019-2025
67 companies · $1,680 in 2025
The $1,680 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,265 · 2020: $791 · 2021: $1,731 · 2022: $2,130 · 2023: $2,927 · 2024: $1,951 · 2025: $1,680.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,558.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,558.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,487.71 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,143.97 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $771.91 | 2019-2025 | Airsupra, Farxiga, Flumist Quadrivalent |
| Bayer Healthcare Pharmaceuticals INC. | $771.61 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $758.28 | 2019-2025 | Jardiance, Synjardy |
| Abbvie INC. | $749.59 | 2020-2025 | Vraylar, Ubrelvy |
| Lilly USA, LLC | $699.99 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Xeris Pharmaceuticals, INC. | $444.06 | 2022-2025 | Gvoke Hypopen |
| Novartis Pharmaceuticals Corporation | $369.80 | 2019-2024 | |
| Idorsia Pharmaceuticals US INC | $326.58 | 2022-2024 | Quviviq |
| Abbott Laboratories | $295.45 | 2021-2025 | Freestyle Libre 3 |
| Amgen INC. | $264.41 | 2019-2025 | Krystexxa, Repatha, Otezla |
| Supernus Pharmaceuticals, INC. | $246.77 | 2019-2023 | Qelbree, Xyosted |
| Grifols USA, LLC | $229.49 | 2019-2025 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $221.87 | 2019-2024 | Yupelri |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Doheny listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.